The state of North Carolina currently has 8 active clinical trials seeking participants for Narcolepsy research studies. These trials are conducted in various cities, including Durham, Charlotte, Winston-Salem and Chapel Hill.
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
Recruiting
The primary purpose of this study is to evaluate the efficacy of single oral doses of E2086 compared to placebo in the treatment of excessive daytime sleepiness (EDS) as assessed by the Maintenance of Wakefulness Test (MWT) in adult participants with narcolepsy type 1 (NT1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Research Carolina Elite, Denver, North Carolina +2 locations
Conditions: Narcolepsy Type 1 (NT1)
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy
Recruiting
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1) or Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/06/2025
Locations: Alkermes Investigational Site, Huntersville, North Carolina
Conditions: Narcolepsy Type 1, Narcolepsy Type 2
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
Recruiting
The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/16/2024
Locations: Alkermes Investigational Site, Denver, North Carolina +1 locations
Conditions: Narcolepsy Type 1
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
Recruiting
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/16/2024
Locations: Alkermes Investigator Site, Denver, North Carolina +1 locations
Conditions: Narcolepsy Type 2
A Study of TAK-861 for the Treatment of Narcolepsy Type 1
Recruiting
The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy... Read More
Gender:
ALL
Ages:
Between 16 years and 70 years
Trial Updated:
12/10/2024
Locations: Takeda Site 2, Denver, North Carolina
Conditions: Narcolepsy Type 1
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
Recruiting
The main aim is to evaluate the safety and tolerability of TAK-861 on participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.
Gender:
ALL
Ages:
Between 16 years and 70 years
Trial Updated:
09/24/2024
Locations: Research Carolina Elite, Denver, North Carolina +1 locations
Conditions: Narcolepsy Type 1
SUNOSI® (Solriamfetol) Pregnancy Registry
Recruiting
The SUNOSI (solriamfetol) Pregnancy Registry is a prospective, multi-country, observational study to evaluate the safety of solriamfetol exposure during pregnancy in women with a diagnosis of narcolepsy or obstructive sleep apnea (OSA).
Gender:
Female
Ages:
All
Trial Updated:
05/09/2024
Locations: Evidera, a PPD business unit, Morrisville, North Carolina +1 locations
Conditions: Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring
WAKIX® (Pitolisant) Pregnancy Registry
Recruiting
The WAKIX (pitolisant) Pregnancy Registry is a US-based, prospective, observational cohort study designed to evaluate the association between pitolisant exposure during pregnancy and subsequent maternal, fetal, and infant outcomes.
Gender:
Female
Ages:
All
Trial Updated:
01/24/2024
Locations: Evidera (PPD), Morrisville, North Carolina
Conditions: Pregnancy Related, Narcolepsy